Stryker (NYSE:SYK) Stock Sold Off Rep. Thomas H. Kean, Jr.

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Stryker Corporation (NYSE:SYK). In a filing disclosed on August 18th, the Representative disclosed that they had sold between $1,001 and $15,000 in Stryker stock on July 22nd. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 7/22/2026.
• Sold $1,001 – $15,000 in shares of Analog Devices (NASDAQ:ADI) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of S&P Global (NYSE:SPGI) on 6/29/2026.
• Sold $1,001 – $15,000 in shares of Markel Group (NYSE:MKL) on 6/29/2026.
• Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 6/29/2026.
• Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 6/24/2026.
• Sold $15,001 – $50,000 in shares of Alphabet (NASDAQ:GOOGL) on 6/24/2026.
• Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 6/22/2026.
• Sold $1,001 – $15,000 in shares of Gildan Activewear (NYSE:GIL) on 6/17/2026.
• Purchased $1,001 – $15,000 in shares of Wheaton Precious Metals (NYSE:WPM) on 6/4/2026.

Stryker Price Performance

Shares of NYSE:SYK opened at $340.20 on Thursday. The firm has a market cap of $130.49 billion, a PE ratio of 35.25, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. The firm’s fifty day moving average is $326.19 and its 200-day moving average is $332.95. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the prior year, the company posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts predict that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is 36.48%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Varma Mutual Pension Insurance Co grew its holdings in shares of Stryker by 10.5% in the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock worth $18,842,000 after acquiring an additional 5,100 shares during the period. QRG Capital Management Inc. grew its holdings in shares of Stryker by 7.4% during the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock worth $21,281,000 after purchasing an additional 4,186 shares during the period. Swedbank AB lifted its position in Stryker by 6.6% during the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock worth $45,349,000 after acquiring an additional 7,934 shares in the last quarter. Crossmark Global Holdings Inc. boosted its position in Stryker by 31.1% in the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock valued at $9,426,000 after buying an additional 6,367 shares during the last quarter. Finally, Royal Bank of Canada grew its stake in Stryker by 6.5% during the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after purchasing an additional 199,863 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on SYK. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a research report on Friday, May 1st. BTIG Research cut their target price on shares of Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. The Goldman Sachs Group reiterated a “neutral” rating and set a $361.00 target price on shares of Stryker in a report on Friday, May 1st. Barclays dropped their price target on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research note on Monday, May 4th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $386.28.

Insiders Place Their Bets

In other news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at $2,088,423. This represents a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 315,370 shares of company stock valued at $98,463,501 over the last 90 days. 4.60% of the stock is owned by company insiders.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.